Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Prevalence of cognitive impairment and its relation to mental health in Danish lymphoma survivors

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual Patient Data Meta-analysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Effect of blood glucose and body weight on image quality in brain [F-18]FDG PET imaging

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Gaël Chételat
  • Javier Arbizu
  • Henryk Barthel
  • Valentina Garibotto
  • Ian Law
  • Silvia Morbelli
  • Elsmarieke van de Giessen
  • Federica Agosta
  • Frederik Barkhof
  • David J Brooks
  • Maria C Carrillo
  • Bruno Dubois
  • Anders M Fjell
  • Giovanni B Frisoni
  • Oskar Hansson
  • Karl Herholz
  • Brian F Hutton
  • Clifford R Jack
  • Adriaan A Lammertsma
  • Susan M Landau
  • Satoshi Minoshima
  • Flavio Nobili
  • Agneta Nordberg
  • Rik Ossenkoppele
  • Wim J G Oyen
  • Daniela Perani
  • Gil D Rabinovici
  • Philip Scheltens
  • Victor L Villemagne
  • Henrik Zetterberg
  • Alexander Drzezga
Vis graf over relationer

Various biomarkers are available to support the diagnosis of neurodegenerative diseases in clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET, which assesses brain amyloid deposition, and 18F-fluorodeoxyglucose (18F-FDG) PET, which assesses glucose metabolism, provide valuable and complementary information. However, uncertainty remains regarding the optimal timepoint, combination, and an order in which these PET biomarkers should be used in diagnostic evaluations because conclusive evidence is missing. Following an expert panel discussion, we reached an agreement on the specific use of the individual biomarkers, based on available evidence and clinical expertise. We propose a diagnostic algorithm with optimal timepoints for these PET biomarkers, also taking into account evidence from other biomarkers, for early and differential diagnosis of neurodegenerative diseases that can lead to dementia. We propose three main diagnostic pathways with distinct biomarker sequences, in which amyloid-PET and 18F-FDG-PET are placed at different positions in the order of diagnostic evaluations, depending on clinical presentation. We hope that this algorithm can support diagnostic decision making in specialist clinical settings with access to these biomarkers and might stimulate further research towards optimal diagnostic strategies.

TidsskriftThe Lancet Neurology
Udgave nummer11
Sider (fra-til)951-962
Antal sider12
StatusUdgivet - nov. 2020

Bibliografisk note

Copyright © 2020 Elsevier Ltd. All rights reserved.

ID: 62405062